Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Erectile Dysfunction | 12 | 2024 | 75 | 7.790 |
Why?
|
Penile Implantation | 9 | 2024 | 14 | 6.620 |
Why?
|
Penile Prosthesis | 10 | 2024 | 24 | 6.390 |
Why?
|
Hypogonadism | 7 | 2024 | 40 | 4.040 |
Why?
|
Penis | 10 | 2024 | 60 | 3.520 |
Why?
|
Testosterone | 6 | 2024 | 276 | 2.540 |
Why?
|
Penile Diseases | 4 | 2022 | 8 | 2.360 |
Why?
|
Prostatic Hyperplasia | 4 | 2023 | 91 | 2.000 |
Why?
|
Urologic Diseases | 3 | 2023 | 44 | 1.980 |
Why?
|
Penile Induration | 3 | 2024 | 7 | 1.900 |
Why?
|
Male | 77 | 2024 | 42411 | 1.790 |
Why?
|
Infertility, Male | 3 | 2023 | 24 | 1.740 |
Why?
|
Quality of Life | 7 | 2023 | 1668 | 1.380 |
Why?
|
Humans | 88 | 2024 | 89357 | 1.330 |
Why?
|
Cardiovascular Diseases | 3 | 2022 | 711 | 1.280 |
Why?
|
Hormone Replacement Therapy | 3 | 2024 | 85 | 1.270 |
Why?
|
Prostatectomy | 8 | 2022 | 477 | 1.180 |
Why?
|
Lower Urinary Tract Symptoms | 2 | 2021 | 67 | 1.170 |
Why?
|
Organ Transplantation | 2 | 2021 | 276 | 1.150 |
Why?
|
Urolithiasis | 2 | 2017 | 4 | 1.090 |
Why?
|
Prostatic Neoplasms | 7 | 2021 | 1769 | 1.040 |
Why?
|
Carcinoma, Renal Cell | 9 | 2019 | 437 | 1.040 |
Why?
|
Orchiectomy | 2 | 2024 | 72 | 1.030 |
Why?
|
Kidney Neoplasms | 10 | 2019 | 638 | 1.030 |
Why?
|
Nephrectomy | 12 | 2019 | 295 | 1.020 |
Why?
|
Sexual Dysfunction, Physiological | 2 | 2022 | 69 | 0.980 |
Why?
|
Suture Techniques | 2 | 2024 | 140 | 0.960 |
Why?
|
Testicular Neoplasms | 2 | 2024 | 113 | 0.960 |
Why?
|
Cachexia | 1 | 2024 | 13 | 0.950 |
Why?
|
Urinary Bladder | 3 | 2017 | 246 | 0.940 |
Why?
|
Sperm Retrieval | 1 | 2024 | 3 | 0.940 |
Why?
|
Semen | 1 | 2023 | 13 | 0.900 |
Why?
|
Penile Neoplasms | 1 | 2023 | 17 | 0.900 |
Why?
|
Vasectomy | 1 | 2023 | 4 | 0.900 |
Why?
|
Fertility Preservation | 1 | 2024 | 23 | 0.900 |
Why?
|
Urinary Sphincter, Artificial | 2 | 2020 | 14 | 0.880 |
Why?
|
Exosomes | 1 | 2023 | 53 | 0.860 |
Why?
|
Postoperative Complications | 10 | 2024 | 2284 | 0.840 |
Why?
|
Penile Erection | 4 | 2023 | 22 | 0.830 |
Why?
|
Hyaluronic Acid | 1 | 2022 | 49 | 0.830 |
Why?
|
Telemedicine | 2 | 2024 | 188 | 0.800 |
Why?
|
Transurethral Resection of Prostate | 1 | 2021 | 10 | 0.790 |
Why?
|
Premature Ejaculation | 1 | 2021 | 1 | 0.780 |
Why?
|
Genitalia | 1 | 2021 | 21 | 0.750 |
Why?
|
Urinary Incontinence, Stress | 2 | 2020 | 196 | 0.750 |
Why?
|
Hyperthyroidism | 1 | 2021 | 75 | 0.750 |
Why?
|
Urinary Bladder Neoplasms | 3 | 2020 | 401 | 0.750 |
Why?
|
Mycophenolic Acid | 2 | 2011 | 84 | 0.750 |
Why?
|
Urinary Tract | 1 | 2021 | 35 | 0.730 |
Why?
|
Transgender Persons | 1 | 2022 | 107 | 0.730 |
Why?
|
Extracorporeal Shockwave Therapy | 1 | 2020 | 2 | 0.730 |
Why?
|
Vaping | 1 | 2021 | 45 | 0.720 |
Why?
|
Urinary Incontinence | 1 | 2022 | 213 | 0.700 |
Why?
|
Thrombosis | 2 | 2021 | 302 | 0.690 |
Why?
|
Urinary Bladder, Neurogenic | 1 | 2020 | 25 | 0.690 |
Why?
|
Electronic Nicotine Delivery Systems | 1 | 2021 | 73 | 0.690 |
Why?
|
Sexual and Gender Minorities | 1 | 2023 | 208 | 0.670 |
Why?
|
Self-Injurious Behavior | 1 | 2021 | 110 | 0.640 |
Why?
|
Retrospective Studies | 22 | 2022 | 9057 | 0.610 |
Why?
|
Middle Aged | 30 | 2024 | 25974 | 0.610 |
Why?
|
Treatment Outcome | 15 | 2024 | 8241 | 0.590 |
Why?
|
Cystocele | 1 | 2016 | 7 | 0.570 |
Why?
|
Immunosuppressive Agents | 2 | 2013 | 975 | 0.560 |
Why?
|
Kidney Transplantation | 3 | 2013 | 850 | 0.540 |
Why?
|
Allografts | 1 | 2016 | 181 | 0.530 |
Why?
|
Skin Transplantation | 1 | 2016 | 184 | 0.510 |
Why?
|
Music Therapy | 1 | 2015 | 2 | 0.510 |
Why?
|
Vagina | 1 | 2016 | 173 | 0.510 |
Why?
|
Aged | 25 | 2023 | 19165 | 0.510 |
Why?
|
Female | 32 | 2023 | 46202 | 0.500 |
Why?
|
Health Care Costs | 1 | 2017 | 235 | 0.500 |
Why?
|
Cystoscopy | 1 | 2015 | 39 | 0.500 |
Why?
|
Edema | 1 | 2014 | 70 | 0.480 |
Why?
|
Ambulatory Surgical Procedures | 1 | 2015 | 75 | 0.470 |
Why?
|
Adenocarcinoma, Mucinous | 1 | 2014 | 48 | 0.470 |
Why?
|
Chronic Pain | 1 | 2016 | 162 | 0.460 |
Why?
|
Kidney | 3 | 2019 | 1147 | 0.460 |
Why?
|
Urology | 4 | 2020 | 117 | 0.460 |
Why?
|
Drainage | 1 | 2014 | 162 | 0.450 |
Why?
|
Prospective Studies | 6 | 2023 | 4289 | 0.440 |
Why?
|
Adult | 20 | 2024 | 26607 | 0.440 |
Why?
|
Bone Neoplasms | 2 | 2014 | 329 | 0.440 |
Why?
|
Fertility | 2 | 2023 | 117 | 0.430 |
Why?
|
Robotic Surgical Procedures | 4 | 2020 | 306 | 0.420 |
Why?
|
Anxiety | 1 | 2015 | 308 | 0.420 |
Why?
|
Hepatitis B, Chronic | 1 | 2013 | 32 | 0.420 |
Why?
|
Arthritis, Reactive | 1 | 2012 | 2 | 0.420 |
Why?
|
Analgesics, Opioid | 2 | 2016 | 444 | 0.420 |
Why?
|
Renal Veins | 2 | 2013 | 28 | 0.420 |
Why?
|
Urography | 1 | 2012 | 45 | 0.420 |
Why?
|
Obesity | 3 | 2020 | 971 | 0.410 |
Why?
|
Pain | 1 | 2015 | 400 | 0.410 |
Why?
|
BCG Vaccine | 1 | 2012 | 35 | 0.410 |
Why?
|
Prevalence | 4 | 2021 | 1243 | 0.400 |
Why?
|
Hematuria | 1 | 2012 | 50 | 0.400 |
Why?
|
Guanine | 1 | 2013 | 207 | 0.400 |
Why?
|
Osteolysis | 1 | 2011 | 14 | 0.400 |
Why?
|
Nephrolithiasis | 1 | 2012 | 25 | 0.400 |
Why?
|
Prosthesis Failure | 2 | 2024 | 116 | 0.390 |
Why?
|
Femoral Neoplasms | 1 | 2011 | 23 | 0.390 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2012 | 73 | 0.390 |
Why?
|
Lateral Ligament, Ankle | 1 | 2011 | 1 | 0.390 |
Why?
|
Urinary Catheterization | 1 | 2011 | 36 | 0.390 |
Why?
|
Adjuvants, Immunologic | 1 | 2012 | 168 | 0.380 |
Why?
|
Motor Activity | 1 | 2014 | 327 | 0.380 |
Why?
|
Osteoblasts | 1 | 2011 | 98 | 0.380 |
Why?
|
Laparoscopy | 5 | 2019 | 773 | 0.380 |
Why?
|
Ankle | 1 | 2011 | 20 | 0.380 |
Why?
|
Transplantation Immunology | 1 | 2011 | 82 | 0.370 |
Why?
|
Femur | 1 | 2011 | 111 | 0.370 |
Why?
|
Carcinoma, Transitional Cell | 1 | 2012 | 171 | 0.370 |
Why?
|
Azathioprine | 1 | 2011 | 124 | 0.370 |
Why?
|
Diet | 1 | 2014 | 442 | 0.360 |
Why?
|
HIV Infections | 3 | 2017 | 840 | 0.360 |
Why?
|
Graft Survival | 2 | 2011 | 900 | 0.360 |
Why?
|
Length of Stay | 6 | 2020 | 736 | 0.360 |
Why?
|
Urinary Fistula | 1 | 2009 | 7 | 0.350 |
Why?
|
Xenograft Model Antitumor Assays | 1 | 2011 | 470 | 0.350 |
Why?
|
Rectal Fistula | 1 | 2009 | 18 | 0.350 |
Why?
|
Prosthesis-Related Infections | 2 | 2020 | 61 | 0.340 |
Why?
|
Cadaver | 5 | 2012 | 185 | 0.330 |
Why?
|
Antiviral Agents | 1 | 2013 | 478 | 0.330 |
Why?
|
Urethra | 2 | 2020 | 115 | 0.330 |
Why?
|
Tomography, X-Ray Computed | 4 | 2019 | 2661 | 0.320 |
Why?
|
Androgen Antagonists | 3 | 2021 | 154 | 0.290 |
Why?
|
Renal Artery | 1 | 2007 | 52 | 0.290 |
Why?
|
Kidney Failure, Chronic | 1 | 2011 | 414 | 0.280 |
Why?
|
Men's Health | 2 | 2024 | 6 | 0.280 |
Why?
|
Ureteroscopy | 2 | 2017 | 38 | 0.270 |
Why?
|
Lithotripsy | 2 | 2017 | 45 | 0.270 |
Why?
|
Surveys and Questionnaires | 3 | 2022 | 2624 | 0.260 |
Why?
|
United States | 5 | 2023 | 6989 | 0.260 |
Why?
|
Knee Joint | 1 | 2007 | 165 | 0.260 |
Why?
|
Cohort Studies | 6 | 2020 | 2872 | 0.260 |
Why?
|
Wounds and Injuries | 1 | 2009 | 259 | 0.260 |
Why?
|
Follow-Up Studies | 6 | 2016 | 3666 | 0.250 |
Why?
|
Pain Measurement | 2 | 2016 | 329 | 0.240 |
Why?
|
Foreign-Body Migration | 1 | 2024 | 39 | 0.230 |
Why?
|
Seminoma | 1 | 2024 | 13 | 0.230 |
Why?
|
Spermatogonia | 1 | 2023 | 13 | 0.230 |
Why?
|
Adolescent | 6 | 2023 | 9263 | 0.230 |
Why?
|
Risk Factors | 8 | 2020 | 5499 | 0.230 |
Why?
|
Cryopreservation | 1 | 2024 | 74 | 0.220 |
Why?
|
Reproductive Techniques, Assisted | 1 | 2023 | 16 | 0.220 |
Why?
|
California | 2 | 2015 | 144 | 0.220 |
Why?
|
Maternal Age | 1 | 2023 | 45 | 0.220 |
Why?
|
Robotics | 2 | 2019 | 269 | 0.220 |
Why?
|
Demography | 2 | 2015 | 183 | 0.220 |
Why?
|
Gels | 1 | 2022 | 49 | 0.210 |
Why?
|
Esthetics | 1 | 2022 | 45 | 0.210 |
Why?
|
Longitudinal Studies | 4 | 2020 | 1072 | 0.210 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2009 | 1096 | 0.210 |
Why?
|
Personal Satisfaction | 1 | 2023 | 63 | 0.210 |
Why?
|
Gender Identity | 1 | 2022 | 53 | 0.210 |
Why?
|
Aged, 80 and over | 5 | 2015 | 6811 | 0.210 |
Why?
|
Insurance, Health | 1 | 2023 | 162 | 0.200 |
Why?
|
Natural Orifice Endoscopic Surgery | 2 | 2012 | 41 | 0.200 |
Why?
|
Syndrome | 1 | 2022 | 449 | 0.200 |
Why?
|
Drug Therapy, Combination | 1 | 2023 | 784 | 0.200 |
Why?
|
North America | 2 | 2024 | 184 | 0.200 |
Why?
|
Kidney Calculi | 2 | 2015 | 343 | 0.200 |
Why?
|
Ejaculation | 1 | 2021 | 9 | 0.200 |
Why?
|
Selective Estrogen Receptor Modulators | 1 | 2021 | 34 | 0.190 |
Why?
|
Aromatase Inhibitors | 1 | 2021 | 29 | 0.190 |
Why?
|
Artificial Intelligence | 1 | 2024 | 322 | 0.190 |
Why?
|
Prostate-Specific Antigen | 2 | 2015 | 360 | 0.190 |
Why?
|
Endoscopy | 2 | 2017 | 350 | 0.190 |
Why?
|
Chronic Disease | 1 | 2024 | 950 | 0.180 |
Why?
|
Sexual Dysfunctions, Psychological | 1 | 2021 | 35 | 0.180 |
Why?
|
Ireland | 2 | 2011 | 9 | 0.180 |
Why?
|
Surgical Flaps | 1 | 2022 | 249 | 0.180 |
Why?
|
Patient Discharge | 2 | 2020 | 320 | 0.180 |
Why?
|
Urethral Stricture | 1 | 2020 | 14 | 0.180 |
Why?
|
Fibrosis | 1 | 2021 | 234 | 0.180 |
Why?
|
Urinary Retention | 1 | 2020 | 42 | 0.170 |
Why?
|
Conservative Treatment | 1 | 2019 | 21 | 0.170 |
Why?
|
Dissection | 2 | 2011 | 44 | 0.170 |
Why?
|
Medicare | 1 | 2023 | 425 | 0.170 |
Why?
|
Patient Satisfaction | 1 | 2023 | 461 | 0.170 |
Why?
|
Abdominal Injuries | 1 | 2019 | 46 | 0.170 |
Why?
|
Urologic Surgical Procedures, Male | 2 | 2020 | 14 | 0.170 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2016 | 1365 | 0.170 |
Why?
|
Genitalia, Male | 1 | 2019 | 24 | 0.160 |
Why?
|
Ultrasonography | 1 | 2021 | 712 | 0.160 |
Why?
|
Priapism | 1 | 2018 | 5 | 0.160 |
Why?
|
Cannabis | 1 | 2019 | 35 | 0.160 |
Why?
|
Prosthesis Implantation | 1 | 2020 | 126 | 0.160 |
Why?
|
Mortality | 1 | 2019 | 149 | 0.160 |
Why?
|
Wounds, Nonpenetrating | 1 | 2019 | 113 | 0.160 |
Why?
|
Disease-Free Survival | 3 | 2016 | 1214 | 0.150 |
Why?
|
Urologic Neoplasms | 1 | 2019 | 84 | 0.150 |
Why?
|
Surgical Wound Infection | 1 | 2020 | 201 | 0.150 |
Why?
|
Nephrolithotomy, Percutaneous | 1 | 2017 | 8 | 0.150 |
Why?
|
Specialization | 1 | 2017 | 66 | 0.150 |
Why?
|
Operative Time | 4 | 2020 | 143 | 0.150 |
Why?
|
Pilot Projects | 2 | 2018 | 871 | 0.140 |
Why?
|
Empyema | 1 | 2017 | 9 | 0.140 |
Why?
|
Neoplasm Staging | 2 | 2015 | 2018 | 0.140 |
Why?
|
Disease Management | 1 | 2019 | 329 | 0.140 |
Why?
|
Asia | 1 | 2017 | 98 | 0.140 |
Why?
|
Neoplasm Grading | 2 | 2016 | 374 | 0.140 |
Why?
|
Australia | 1 | 2017 | 101 | 0.140 |
Why?
|
Urinary Bladder Diseases | 1 | 2017 | 41 | 0.140 |
Why?
|
Animals | 5 | 2023 | 27371 | 0.140 |
Why?
|
Endocrinology | 1 | 2017 | 50 | 0.140 |
Why?
|
Solvents | 1 | 2016 | 96 | 0.140 |
Why?
|
Europe | 1 | 2017 | 321 | 0.140 |
Why?
|
Ischemia | 1 | 2018 | 251 | 0.140 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 860 | 0.140 |
Why?
|
Mice | 3 | 2023 | 11761 | 0.130 |
Why?
|
Cryosurgery | 1 | 2016 | 54 | 0.130 |
Why?
|
Risk Assessment | 2 | 2016 | 2303 | 0.130 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 46 | 0.130 |
Why?
|
Guideline Adherence | 1 | 2017 | 230 | 0.130 |
Why?
|
Age Factors | 3 | 2016 | 1870 | 0.130 |
Why?
|
Multivariate Analysis | 2 | 2015 | 988 | 0.130 |
Why?
|
Databases, Factual | 2 | 2019 | 856 | 0.130 |
Why?
|
Young Adult | 3 | 2023 | 6312 | 0.130 |
Why?
|
Morbidity | 3 | 2020 | 149 | 0.130 |
Why?
|
Graft Rejection | 2 | 2011 | 1070 | 0.130 |
Why?
|
Platelet Aggregation Inhibitors | 1 | 2016 | 143 | 0.120 |
Why?
|
Bacteriuria | 1 | 2014 | 10 | 0.120 |
Why?
|
Patient Protection and Affordable Care Act | 1 | 2015 | 67 | 0.120 |
Why?
|
Family Health | 1 | 2015 | 162 | 0.120 |
Why?
|
Nephrostomy, Percutaneous | 1 | 2014 | 32 | 0.120 |
Why?
|
Epstein-Barr Virus Infections | 1 | 2015 | 55 | 0.120 |
Why?
|
Leiomyosarcoma | 1 | 2015 | 45 | 0.120 |
Why?
|
Guidelines as Topic | 1 | 2016 | 160 | 0.120 |
Why?
|
Escherichia coli Infections | 1 | 2014 | 35 | 0.120 |
Why?
|
Systemic Inflammatory Response Syndrome | 1 | 2014 | 51 | 0.120 |
Why?
|
Logistic Models | 2 | 2015 | 1213 | 0.120 |
Why?
|
Insurance Coverage | 1 | 2015 | 120 | 0.120 |
Why?
|
Drug Resistance, Multiple, Bacterial | 1 | 2014 | 51 | 0.120 |
Why?
|
Veterans | 1 | 2015 | 84 | 0.120 |
Why?
|
Primary Health Care | 1 | 2017 | 351 | 0.120 |
Why?
|
Membrane Proteins | 2 | 2012 | 1224 | 0.120 |
Why?
|
5-alpha Reductase Inhibitors | 1 | 2014 | 12 | 0.110 |
Why?
|
Fever | 1 | 2014 | 128 | 0.110 |
Why?
|
Recurrence | 1 | 2017 | 1144 | 0.110 |
Why?
|
Rats | 1 | 2020 | 4041 | 0.110 |
Why?
|
Regression Analysis | 1 | 2015 | 590 | 0.110 |
Why?
|
Skin | 1 | 2016 | 582 | 0.110 |
Why?
|
Psychiatric Status Rating Scales | 1 | 2015 | 492 | 0.110 |
Why?
|
Lamivudine | 1 | 2013 | 13 | 0.110 |
Why?
|
Proportional Hazards Models | 1 | 2015 | 851 | 0.110 |
Why?
|
Hepatitis B virus | 1 | 2013 | 44 | 0.110 |
Why?
|
Medicaid | 1 | 2015 | 232 | 0.110 |
Why?
|
Pelvis | 1 | 2013 | 96 | 0.100 |
Why?
|
Virus Activation | 1 | 2013 | 42 | 0.100 |
Why?
|
Cost-Benefit Analysis | 1 | 2015 | 461 | 0.100 |
Why?
|
Radiography | 1 | 2014 | 809 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2017 | 601 | 0.100 |
Why?
|
Muscular Dystrophies, Limb-Girdle | 1 | 2012 | 15 | 0.100 |
Why?
|
Chloride Channels | 1 | 2012 | 42 | 0.100 |
Why?
|
Pyrroles | 1 | 2013 | 187 | 0.100 |
Why?
|
Rupture | 1 | 2011 | 61 | 0.100 |
Why?
|
Cystostomy | 1 | 2011 | 15 | 0.100 |
Why?
|
Vena Cava, Inferior | 1 | 2013 | 145 | 0.100 |
Why?
|
Body Weights and Measures | 1 | 2011 | 27 | 0.100 |
Why?
|
Peritoneum | 1 | 2011 | 57 | 0.100 |
Why?
|
Lymph Node Excision | 1 | 2013 | 220 | 0.100 |
Why?
|
Thrombectomy | 1 | 2013 | 180 | 0.090 |
Why?
|
X-Ray Microtomography | 1 | 2011 | 90 | 0.090 |
Why?
|
Survival Rate | 2 | 2015 | 1901 | 0.090 |
Why?
|
Mice, SCID | 1 | 2011 | 261 | 0.090 |
Why?
|
Indoles | 1 | 2013 | 314 | 0.090 |
Why?
|
Heart Atria | 1 | 2013 | 282 | 0.090 |
Why?
|
Receptors, Androgen | 1 | 2011 | 123 | 0.090 |
Why?
|
Sepsis | 1 | 2014 | 321 | 0.090 |
Why?
|
Neoplasm Invasiveness | 1 | 2012 | 576 | 0.090 |
Why?
|
Urologic Surgical Procedures | 1 | 2012 | 147 | 0.090 |
Why?
|
Osteoporotic Fractures | 1 | 2011 | 47 | 0.090 |
Why?
|
Heart Diseases | 1 | 2013 | 298 | 0.090 |
Why?
|
Cyclosporine | 1 | 2011 | 237 | 0.090 |
Why?
|
Venous Thrombosis | 1 | 2013 | 253 | 0.090 |
Why?
|
Child | 3 | 2011 | 7174 | 0.090 |
Why?
|
Osteoporosis | 1 | 2011 | 122 | 0.090 |
Why?
|
Postoperative Care | 1 | 2011 | 231 | 0.090 |
Why?
|
Trauma Severity Indices | 2 | 2019 | 44 | 0.090 |
Why?
|
Plant Extracts | 1 | 2011 | 245 | 0.080 |
Why?
|
Cell Line, Tumor | 2 | 2012 | 2558 | 0.080 |
Why?
|
Ependymoma | 1 | 2009 | 18 | 0.080 |
Why?
|
Neoplasms | 1 | 2024 | 3041 | 0.080 |
Why?
|
Spinal Neoplasms | 1 | 2009 | 49 | 0.080 |
Why?
|
Epigenesis, Genetic | 1 | 2012 | 507 | 0.080 |
Why?
|
DNA Methylation | 1 | 2012 | 657 | 0.070 |
Why?
|
Cystectomy | 2 | 2020 | 110 | 0.070 |
Why?
|
Tendon Injuries | 1 | 2007 | 36 | 0.070 |
Why?
|
Disease Models, Animal | 1 | 2014 | 2366 | 0.070 |
Why?
|
Infant | 2 | 2011 | 3160 | 0.070 |
Why?
|
Ligaments, Articular | 1 | 2007 | 38 | 0.070 |
Why?
|
Menisci, Tibial | 1 | 2007 | 26 | 0.070 |
Why?
|
Blood Transfusion | 2 | 2019 | 169 | 0.070 |
Why?
|
Tendons | 1 | 2007 | 44 | 0.070 |
Why?
|
Child, Preschool | 2 | 2011 | 3731 | 0.070 |
Why?
|
Gene Expression Profiling | 1 | 2012 | 1431 | 0.070 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2011 | 1265 | 0.070 |
Why?
|
Severity of Illness Index | 1 | 2011 | 1840 | 0.060 |
Why?
|
Diagnosis, Differential | 1 | 2009 | 1597 | 0.060 |
Why?
|
Wound Healing | 1 | 2007 | 359 | 0.060 |
Why?
|
Hypospadias | 1 | 2024 | 6 | 0.060 |
Why?
|
Blood Loss, Surgical | 2 | 2016 | 115 | 0.060 |
Why?
|
Patient Readmission | 2 | 2019 | 352 | 0.060 |
Why?
|
Comorbidity | 2 | 2019 | 949 | 0.060 |
Why?
|
Biomarkers, Tumor | 1 | 2011 | 1549 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2009 | 782 | 0.050 |
Why?
|
Antineoplastic Agents | 1 | 2013 | 2415 | 0.050 |
Why?
|
Sexual Behavior | 1 | 2024 | 311 | 0.050 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 3448 | 0.050 |
Why?
|
Mutation | 1 | 2012 | 4143 | 0.040 |
Why?
|
Pain, Postoperative | 2 | 2013 | 252 | 0.040 |
Why?
|
Reproducibility of Results | 2 | 2019 | 2758 | 0.040 |
Why?
|
Outpatients | 1 | 2019 | 100 | 0.040 |
Why?
|
Renal Insufficiency | 1 | 2019 | 98 | 0.040 |
Why?
|
Propensity Score | 1 | 2019 | 147 | 0.040 |
Why?
|
Trauma Centers | 1 | 2019 | 146 | 0.040 |
Why?
|
Patient Simulation | 1 | 2018 | 42 | 0.040 |
Why?
|
Intraoperative Complications | 1 | 2019 | 188 | 0.040 |
Why?
|
Anuria | 1 | 2017 | 6 | 0.040 |
Why?
|
Minimally Invasive Surgical Procedures | 1 | 2019 | 253 | 0.040 |
Why?
|
Therapeutic Irrigation | 1 | 2017 | 61 | 0.040 |
Why?
|
Reoperation | 1 | 2019 | 599 | 0.040 |
Why?
|
Urinary Diversion | 1 | 2017 | 42 | 0.030 |
Why?
|
Coronary Thrombosis | 1 | 2016 | 14 | 0.030 |
Why?
|
Perioperative Period | 1 | 2016 | 25 | 0.030 |
Why?
|
Educational Measurement | 1 | 2018 | 231 | 0.030 |
Why?
|
Inpatients | 1 | 2019 | 310 | 0.030 |
Why?
|
Body Mass Index | 1 | 2019 | 773 | 0.030 |
Why?
|
Survival Analysis | 1 | 2019 | 1534 | 0.030 |
Why?
|
Quality Improvement | 1 | 2019 | 451 | 0.030 |
Why?
|
Aspirin | 1 | 2016 | 159 | 0.030 |
Why?
|
Tumor Burden | 1 | 2016 | 308 | 0.030 |
Why?
|
SEER Program | 1 | 2015 | 197 | 0.030 |
Why?
|
Tosyl Compounds | 1 | 2014 | 15 | 0.030 |
Why?
|
Cost of Illness | 1 | 2015 | 147 | 0.030 |
Why?
|
Anilides | 1 | 2014 | 48 | 0.030 |
Why?
|
Heterografts | 1 | 2014 | 102 | 0.030 |
Why?
|
Education, Medical, Graduate | 1 | 2018 | 393 | 0.030 |
Why?
|
Nitriles | 1 | 2014 | 160 | 0.030 |
Why?
|
Curriculum | 1 | 2018 | 568 | 0.030 |
Why?
|
Lymphocele | 1 | 2013 | 6 | 0.030 |
Why?
|
Neoplastic Cells, Circulating | 1 | 2013 | 72 | 0.030 |
Why?
|
Biopsy | 1 | 2016 | 1184 | 0.030 |
Why?
|
Anoctamins | 1 | 2012 | 1 | 0.030 |
Why?
|
Finland | 1 | 2012 | 28 | 0.030 |
Why?
|
Creatine Kinase | 1 | 2012 | 52 | 0.030 |
Why?
|
Cardiopulmonary Bypass | 1 | 2013 | 157 | 0.030 |
Why?
|
Genes, Recessive | 1 | 2012 | 87 | 0.030 |
Why?
|
Disease Progression | 1 | 2016 | 1489 | 0.020 |
Why?
|
Forecasting | 1 | 2013 | 306 | 0.020 |
Why?
|
Serenoa | 1 | 2011 | 1 | 0.020 |
Why?
|
Combined Modality Therapy | 1 | 2015 | 1719 | 0.020 |
Why?
|
Muscle Weakness | 1 | 2012 | 60 | 0.020 |
Why?
|
Rectum | 1 | 2012 | 148 | 0.020 |
Why?
|
Abdomen | 1 | 2012 | 122 | 0.020 |
Why?
|
Acidosis | 1 | 2011 | 55 | 0.020 |
Why?
|
Real-Time Polymerase Chain Reaction | 1 | 2012 | 282 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2017 | 788 | 0.020 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2013 | 307 | 0.020 |
Why?
|
Age of Onset | 1 | 2012 | 312 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 502 | 0.020 |
Why?
|
Absorptiometry, Photon | 1 | 2011 | 99 | 0.020 |
Why?
|
Time Factors | 1 | 2020 | 5338 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2012 | 221 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 887 | 0.020 |
Why?
|
Blotting, Western | 1 | 2012 | 794 | 0.020 |
Why?
|
Phytotherapy | 1 | 2011 | 136 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2012 | 780 | 0.020 |
Why?
|
Promoter Regions, Genetic | 1 | 2012 | 956 | 0.020 |
Why?
|
Patient Selection | 1 | 2013 | 684 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2013 | 548 | 0.020 |
Why?
|
Tissue Array Analysis | 1 | 2009 | 127 | 0.020 |
Why?
|
Muscle, Skeletal | 1 | 2012 | 468 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2013 | 605 | 0.020 |
Why?
|
Incidence | 1 | 2013 | 1595 | 0.020 |
Why?
|
World Health Organization | 1 | 2009 | 106 | 0.020 |
Why?
|
Prognosis | 1 | 2016 | 3783 | 0.020 |
Why?
|
Cytoplasm | 1 | 2009 | 284 | 0.020 |
Why?
|
Genetic Testing | 1 | 2012 | 537 | 0.020 |
Why?
|
Sutures | 1 | 2007 | 53 | 0.020 |
Why?
|
Tensile Strength | 1 | 2007 | 80 | 0.020 |
Why?
|
Genotype | 1 | 2012 | 1849 | 0.020 |
Why?
|
Random Allocation | 1 | 2007 | 327 | 0.020 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 432 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2009 | 599 | 0.020 |
Why?
|
DNA | 1 | 2012 | 1308 | 0.020 |
Why?
|
Swine | 1 | 2007 | 582 | 0.020 |
Why?
|
Phenotype | 1 | 2012 | 2440 | 0.020 |
Why?
|
Genetic Variation | 1 | 2012 | 1374 | 0.020 |
Why?
|
Immunohistochemistry | 1 | 2009 | 1799 | 0.010 |
Why?
|
Gene Expression | 1 | 2009 | 1310 | 0.010 |
Why?
|